Cumberland Pharmaceuticals Statistics
Share Statistics
Cumberland Pharmaceuticals has 13.97M
shares outstanding. The number of shares has increased by -1.57%
in one year.
| Shares Outstanding | 13.97M |
| Shares Change (YoY) | -1.57% |
| Shares Change (QoQ) | -0.53% |
| Owned by Institutions (%) | 13.11% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 195 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 86.19K, so 0.62% of the outstanding
shares have been sold short.
| Short Interest | 86.19K |
| Short % of Shares Out | 0.62% |
| Short % of Float | 1.11% |
| Short Ratio (days to cover) | 3.01 |
Valuation Ratios
The PE ratio is -5.14 and the forward
PE ratio is -8.56.
Cumberland Pharmaceuticals's PEG ratio is
-1.13.
| PE Ratio | -5.14 |
| Forward PE | -8.56 |
| PS Ratio | 0.88 |
| Forward PS | 1.5 |
| PB Ratio | 1.46 |
| P/FCF Ratio | -42.08 |
| PEG Ratio | -1.13 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Cumberland Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15,
with a Debt / Equity ratio of 0.9.
| Current Ratio | 1.15 |
| Quick Ratio | 1.03 |
| Debt / Equity | 0.9 |
| Debt / EBITDA | 112.77 |
| Debt / FCF | -25.98 |
| Interest Coverage | -11.73 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $416,131.26 |
| Profits Per Employee | $-71,206.26 |
| Employee Count | 91 |
| Asset Turnover | 0.5 |
| Inventory Turnover | 1.65 |
Taxes
| Income Tax | -22.67K |
| Effective Tax Rate | 0.35% |
Stock Price Statistics
The stock price has increased by 205.84% in the
last 52 weeks. The beta is -0.35, so Cumberland Pharmaceuticals's
price volatility has been lower than the market average.
| Beta | -0.35 |
| 52-Week Price Change | 205.84% |
| 50-Day Moving Average | 4.78 |
| 200-Day Moving Average | 2.67 |
| Relative Strength Index (RSI) | 52.45 |
| Average Volume (20 Days) | 130,557 |
Income Statement
In the last 12 months, Cumberland Pharmaceuticals had revenue of 37.87M
and earned -6.48M
in profits. Earnings per share was -0.46.
| Revenue | 37.87M |
| Gross Profit | 31.28M |
| Operating Income | -7.1M |
| Net Income | -6.48M |
| EBITDA | 182.42K |
| EBIT | -5.86M |
| Earnings Per Share (EPS) | -0.46 |
Full Income StatementBalance Sheet
The company has 17.96M in cash and 20.57M in
debt, giving a net cash position of -2.61M.
| Cash & Cash Equivalents | 17.96M |
| Total Debt | 20.57M |
| Net Cash | -2.61M |
| Retained Earnings | -23.97M |
| Total Assets | 75.58M |
| Working Capital | 4.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -612.19K
and capital expenditures -179.71K, giving a free cash flow of -791.9K.
| Operating Cash Flow | -612.19K |
| Capital Expenditures | -179.71K |
| Free Cash Flow | -791.9K |
| FCF Per Share | -0.06 |
Full Cash Flow StatementMargins
Gross margin is 82.61%, with operating and profit margins of -18.75% and -17.11%.
| Gross Margin | 82.61% |
| Operating Margin | -18.75% |
| Pretax Margin | -17.08% |
| Profit Margin | -17.11% |
| EBITDA Margin | 0.48% |
| EBIT Margin | -18.75% |
| FCF Margin | -2.09% |
